The effect of 1-(4,5-dihydro-1H-imidazol-2-yl) isoquinoline on monoamine release and turnover in the rat frontal cortex

Neuroscience Letters

Volumn 422, Issue 2, 2007, Pages 109-113

  Abu Ghazaleh, Haya ^a   Lalies, Maggie D ^b   Husbands, Stephen M ^c   Nutt, David J ^a   Hudson, Alan L ^b  

^a Psychopharmacology Unit   (United Kingdom)

^b UNIVERSITY OF ALBERTA   (Canada)

^c University of Bath   (United Kingdom)

Author keywords

BU98008 (1 (4,5 dihydro 1H imidazol 2 yl) isoquinoline); Imidazoline2 binding site; Microdialysis; Monoamine release

Indexed keywords

1 (4,5 DIHYDRO 1H IMIDAZOL 2 YL)ISOQUINOLINE; 3,4 DIHYDROXYPHENYLACETIC ACID; BU 98008; DOPAMINE; ISOQUINOLINE DERIVATIVE; NORADRENALIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG DOSE COMPARISON; EXPERIMENTAL MODEL; FRONTAL CORTEX; IN VIVO STUDY; MALE; MICRODIALYSIS; MONOAMINE METABOLISM; MONOAMINE RELEASE; NONHUMAN; NORADRENALIN BRAIN LEVEL; NORADRENALIN RELEASE; PRIORITY JOURNAL; RAT; SEROTONINERGIC TRANSMISSION;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; BIOGENIC MONOAMINES; BRAIN CHEMISTRY; DOPAMINE; EXTRACELLULAR FLUID; FRONTAL LOBE; IMIDAZOLES; ISOQUINOLINES; LIGANDS; MALE; MICRODIALYSIS; MOLECULAR STRUCTURE; NOREPINEPHRINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DRUG; SEROTONIN;

EID: 34447515232     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2007.05.054     Document Type: Article

References (27)

1. Abu Ghazaleh H., Lalies M.D., Tyacke R.J., Husbands S.M., Rees C., Hudson N., Kwan J., Purchase L., Nutt D.J., and Hudson A.L. Preliminary evaluation of the affinity of isoquinoline-containing compounds at imidazoline1 binding sites. Proc. Br. Pharmacol. Soc. (2004). http://www.pa2online.org/scripts/relatedVol2Issue2abst063P.html
2. 2 binding sites. Proc. Br. Pharmacol. Soc. (2004). http://www.pa2online.org./scripts/relatedVol2Issue4.asp
3. Anderson N.J., Seif I., Nutt D.J., Hudson A.L., and Robinson E.S. Autoradiographical distribution of imidazoline binding sites in monoamine oxidase A deficient mice. J. Neurochem. 96 (2006) 1551-1559
4. Baum S.S., Hill R., and Rommelspacher H. Harman-induced changes of extracellular concentrations of neurotransmitters in the nucleus accumbens of rats. Eur. J. Pharmacol. 314 (1996) 75-82
5. Bousquet P., Dontenwill M., Greney H., and Feldman J. Imidazoline receptors in cardiovascular and metabolic diseases. J. Cardiovasc. Pharmacol. 35 (2000) S21-S25
6. Bousquet P., Feldman J., and Schwartz J. Central cardiovascular effects of alpha adrenergic drugs: differences between catecholamines and imidazolines. J. Pharmacol. Exp. Ther. 230 (1984) 232-236
7. Bousquet P., Greney H., Bruban V., Schann S., Ehrhardt J.D., Monassier L., and Feldman J. I(1) imidazoline receptors involved in cardiovascular regulation: where are we and where are we going?. Ann. N Y Acad. Sci. 1009 (2003) 228-233
8. Callado L.F., Maeztu A.I., Ballesteros J., Gutierrez M., and Meana J.J. Differential [(3)H]idazoxan and [(3)H]2-(2-benzofuranyl)-2-imidazoline (2-BFI) binding to imidazoline I(2) receptors in human postmortem frontal cortex. Eur. J. Pharmacol. 423 (2001) 109-114
9. Chan S.L., Brown C.A., Scarpello K.E., and Morgan N.G. The imidazoline site involved in control of insulin secretion: characteristics that distinguish it from I1- and I2-sites. Br. J. Pharmacol. 112 (1994) 1065-1070
10. Dardonville C., and Rozas I. Imidazoline binding sites and their ligands: an overview of the different chemical structures. Med. Res. Rev. 24 (2004) 639-661
11. Eglen R.M., Hudson A.L., Kendall D.A., Nutt D.J., Morgan N.G., Wilson V.G., and Dillon M.P. 'Seeing through a glass darkly': casting light on imidazoline 'I' sites. Trends Pharmacol. Sci. 19 (1998) 381-390
12. Finn D.P., Marti O., Harbuz M.S., Valles A., Belda X., Marquez C., Jessop D.S., Lalies M.D., Armario A., Nutt D.J., and Hudson A.L. Behavioral, neuroendocrine and neurochemical effects of the imidazoline I2 receptor selective ligand BU224 in naive rats and rats exposed to the stress of the forced swim test. Psychopharmacology 167 (2003) 195-202
13. Gargalidis-Moudanos C., Pizzinat N., Javoy-Agid F., Remaury A., and Parini A. I2-imidazoline binding sites and monoamine oxidase activity in human postmortem brain from patients with Parkinson's disease. Neurochem. Int. 30 (1997) 31-36
14. Hudson A.L., Gough R., Tyacke R., Lione L., Lalies M., Lewis J., Husbands S., Knight P., Murray F., Hutson P., and Nutt D.J. Novel selective compounds for the investigation of imidazoline receptors. Ann. N Y Acad. Sci. 881 (1999) 81-91
15. Lalies M.D., Hibell A., Hudson A.L., and Nutt D.J. Inhibition of central monoamine oxidase by imidazoline2 site-selective ligands. Ann. N Y Acad. Sci. 881 (1999) 114-117
16. Lione L.A., Nutt D.J., and Hudson A.L. [3H]2-(2-benzofuranyl)-2-imidazoline: a new selective high affinity radioligand for the study of rabbit brain imidazoline I2 receptors. Eur. J. Pharmacol. 304 (1996) 221-229
17. MacInnes N., and Handley S.L. Potential serotonergic and noradrenergic involvement in the discriminative stimulus effects of the selective imidazoline I2-site ligand 2-BFI. Pharmacol. Biochem. Behav. 75 (2003) 427-433
18. Matsumoto M., Yoshioka M., Togashi H., Mori K., Ueno K., and Saito H. Effects of idazoxan on dopamine release in the prefrontal cortex of freely moving rats. Eur. J. Pharmacol. 343 (1998) 165-170
19. Nutt D.J., French N., Handley S., Hudson A., Husbands S., Jackson H., Jordan S., Lalies M.D., Lewis J., Lione L., Mallard N., and Pratt J. Functional studies of specific imidazoline-2 receptor ligands. Ann. NY Acad. Sci. 763 (1995) 125-139
20. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1986), Academic Press, San Diego, CA
21. Raddatz R., and Lanier S.M. Relationship between imidazoline/guanidinium receptive sites and monoamine oxidase A and B. Neurochem. Int. 30 (1997) 109-117
22. Sastre-Coll A., Esteban S., and Garcia-Sevilla J.A. Effects of 2-(2-benzofuranyl)-2-imidazoline (2-BFI) on dopamine synthesis in rat striatum in vivo. Ann. N Y Acad. Sci. 881 (1999) 364
23. Sastre-Coll A., Esteban S., and Garcia-Sevilla J.A. Effects of imidazoline receptor ligands on monoamine synthesis in the rat brain in vivo. Naunyn-Schmiedebergs Arch. Pharmacol. 360 (1999) 50-62
24. Sastre-Coll A., Esteban S., Miralles A., Zanetti R., and Garcia-Sevilla J.A. The imidazoline receptor ligand 2-(2-benzofuranyl)-2-imidazoline is a dopamine-releasing agent in the rat striatum in vivo. Neurosci. Lett. 301 (2001) 29-32
25. Tesson F., Limon-Boulez I., Urban P., Puype M., Vandekerckhove J., Coupry I., Pompon D., and Parini A. Localization of I2-imidazoline binding sites on monoamine oxidases. J. Biol. Chem. 270 (1995) 9856-9861
26. Ugedo L., Pineda J., Martin-Ruiz R., Ruiz-Ortega J.A., and Artigas F. Imidazoline-induced inhibition of firing rate of 5-HT neurons in rat dorsal raphe by modulation of extracellular 5-HT levels. Ann. N Y Acad. Sci. 881 (1999) 365-368
27. Yamamoto B.K., and Novotney S. Regulation of extracellular dopamine by the norepinephrine transporter. J. Neurochem. 71 (1998) 274-280